Table 2.
Toxicity profile of the FEAM regimen
| Grade 1 | Grade 2 | Grade 3 | Grade 4 | None | |
|---|---|---|---|---|---|
| Type of toxicity | |||||
| Mucositis | 27 | 34·4 | 11·5 | 3·3 | 23·8 |
| Diarrhoea | 33·6 | 32 | 5·7 | 0 | 28·7 |
| CINV | 30·3 | 34·4 | 6·6 | 0 | 28·7 |
| Liver | 1·6 | 2·5 | 0 | 0 | 95·9 |
| Renal | 0 | 0 | 0 | 0 | 100 |
| Pulmonary | 0 | 0 | 0 | 0 | 100 |
Data are reported as percent of patients with and without toxicity. Adverse events are graded according to the National Cancer Institute Common Terminology Criteria Version 4.0.
FEAM, fotemustine, etoposide, cytarabine, melphalan; CINV, chemotherapy‐induced nausea and vomiting.